News from the FDA/CDC

FDA: Fluoroquinolone use not linked to retina detachment, aortic problems


 

The Food and Drug Administration has found no evidence of a link between fluoroquinolone usage and retinal detachment or aortic aneurysm and dissection, according to a new Drug Safety Communication update on potential serious, disabling side effects of oral and injectable fluoroquinolone antibiotics.

Fluoroquinolones are used to treat acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections.

FDA icon Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License
In a safety communication published May 12, 2016, the FDA noted that serious side effects were possible from fluoroquinolone usage and that fluoroquinolones should only be prescribed when no other treatment options are possible.

However, after reviewing patient cases and study findings, the FDA said the evidence didn’t support an association between fluoroquinolone usage and potential retinal or aortic dangers, according to its May 10, 2017, Drug Safety Communication update.

Serious side effects associated with fluoroquinolone use include hallucination, depression, suicidal thoughts, tendinitis and tendon rupture, a “pins and needles” feeling in the arms and legs, joint pain and swelling, skin rash, and severe diarrhea.

“We will continue to assess safety issues with fluoroquinolones, and will update the public if additional actions are needed,” the FDA said in a statement.

Recommended Reading

Anthony Fauci faces the ‘perpetual challenge’ of emerging infections
MDedge Family Medicine
Skin testing and decision support can clarify penicillin allergy
MDedge Family Medicine
After the epidemic, Ebola’s destructive power still haunts survivors
MDedge Family Medicine
WHO’s malaria pilot vaccine: No silver bullet, but a potential strike at malaria’s heart
MDedge Family Medicine
Medicine’s revenge against traveler’s diarrhea
MDedge Family Medicine
Rotavirus vaccination in last decade cuts AGE hospitalization
MDedge Family Medicine
U.S. yellow fever vaccine stocks could be depleted within months
MDedge Family Medicine
Dalbavancin proves highly effective in osteomyelitis
MDedge Family Medicine
Consider strongyloidiasis before giving oral steroids
MDedge Family Medicine
Lower-dose aluminum hydroxide–adjuvanted polio vaccine noninferior to standard IPV
MDedge Family Medicine

Related Articles